Burton EM, Milton DR, Tetzlaff MT, Wani K, et al. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. J Clin Oncol 2025 Jul 10:JCO2500494. doi: 10.1200/JCO-25-00494.
PMID: 40638872